Inside the research
Amphastar Pharmaceuticals, Inc.
AMPH Research profile · latest available data
Price overview
$26.13
▼ -0.14 (-0.5%)
| 52w hi | $29.40 |
|---|---|
| 52w lo | $16.87 |
| Vol | 376.90K |
| As of | 25 Sep 2026 |
The Verdict
Our score +0.25
| Short | +0.10 |
|---|---|
| Medium | +0.35 |
| Long | +0.33 |
computed 2026-09-27
Key fundamentals
Amphastar Pharmaceuticals, Inc.
Healthcare · Drug Manufacturers - Specialty & Generic
| Market cap | $1.11B |
|---|---|
| Enterprise value | $1.51B |
| Trailing P/E | 15.46x |
| Forward P/E | 8.21x |
| EV / EBITDA | 7.76x |
| P / S (ttm) | 1.52x |
| Profit margin | 10.8% |
| Return on equity | 10.3% |
| Revenue growth | +5.4% |
| Earnings growth | +4.7% |
| Debt / equity | 89.61 |
Layer Breakdown
| Layer | Raw | Contribution |
|---|---|---|
| Fundamental | +0.25 | |
| Sector | +0.08 | |
| Technical | +0.10 | |
| Earnings | +0.00 | |
| Sentiment | +0.00 |
macro × 1.00 · 2026-09-27
Business overview
Amphastar Pharmaceuticals, Inc., a bio-pharmaceutical company, develops, manufactures, markets, and sells generic and proprietary injectable, inhalation, and intranasal products in the United States, China, and France. It offers BAQSIMI, a dry nasal spray used in an emergency for the treatment of severe hypoglycemia; Primatene MIST, an epinephrine inhalation product for the temporary relief of mild symptoms of intermittent asthma; Glucagon for injection emergency kit; Enoxaparin, an injectable form of low molecular weight heparin for the prevention and treatment of deep vein thrombosis; and REXTOVY and Naloxone for opioid overdose. The company also provides Cortrosyn, a lyophilized power for use as a diagnostic agent in the screening of patients with adrenocortical insufficiency; Amphadase, a bovine-sourced hyaluronidase injection; Epinephrine injection for allergic reactions; Lidocaine jelly, an anesthetic product for urological procedures; Lidocaine topical solution for various procedures; Phytonadione injection, a vitamin K1 injection for newborn babies; and emergency syringe products, including atropine, calcium chloride, dextrose, epinephrine, lidocaine, and sodium bicarbonate. In addition, it offers Albuterol sulfate inhalation aerosol for the treatment or prevention of bronchospasm; Iron sucrose injection, an iron replacement product for the treatment of iron deficiency anemia in patients with chronic kidney disease; Teriparatide injection for managing daily osteoporosis therapy; and Ipratropium Bromide HFA inhalation aerosol, an anticholinergic indicated for the maintenance treatment of bronchospasm associated with chronic obstructive pulmonary disease. Further, the company provides active pharmaceutical ingredient (API) products, such as Recombinant Human Insulin and porcine insulin API. The company was founded in 1996 and is headquartered in Rancho Cucamonga, California.
Risk Metrics
| Beta vs SPX | 0.62 |
|---|---|
| Corr SPX | 0.21 |
| Annual vol | 47.3% |
| Annual ret | -20.0% |
| Sharpe | -0.42 |
| Max DD | -68.4% |
Window: 504 trading days (504 obs)
Analyst Coverage
| Mean PT | $26.43 |
|---|---|
| High / Low | $30.00 / $22.00 |
| Median | $25.00 |
| Analysts | 7 |
| Strong Buy | 1 | |
|---|---|---|
| Buy | 1 | |
| Hold | 5 | |
| Sell | 0 | |
| Strong Sell | 0 |
Recent rating actions
| 2026-05-08 | Needham | → Hold |
| 2026-04-21 | Jefferies | → Hold |
| 2026-04-08 | Barclays | → Equal-Weight |
| 2026-02-27 | Wells Fargo | → Overweight |
| 2026-02-27 | Needham | → Buy |
| 2025-12-09 | Barclays | → Equal-Weight |
Material Events
| Date | Event | 8-K |
|---|---|---|
| 2026-08-06 | Earnings Release, Exhibits | read |
| 2026-07-13 | Officer / Director Change | read |
| 2026-07-08 | Other Material Event | read |
| 2026-06-03 | Shareholder Vote | read |
| 2026-05-07 | Earnings Release, Exhibits | read |
| 2026-03-16 | Other Material Event | read |
| 2026-03-06 | Officer / Director Change, Exhibits | read |
| 2026-03-06 | Material Agreement, Exhibits | read |
| 2026-02-26 | Earnings Release, Exhibits | read |
| 2026-01-12 | Material Agreement, Reg FD Disclosure… | read |
| 2025-11-06 | Earnings Release, Exhibits | read |
| 2025-10-24 | Material Agreement | read |
Insider Trades
| Date | Insider | Role | Action | Shares | Value |
|---|---|---|---|---|---|
| 2026-08-11 | PRINS RICHARD K | Director | Sell | 7.97K | $161.85K |
| 2026-08-07 | PETERS WILLIAM J | Director, Officer, CFO, E | Option exercise | 5.05K | $100.00K |
| 2026-08-07 | PETERS WILLIAM J | Director, Officer, CFO, E | Sell | 8.18K | $183.89K |
| 2026-07-09 | Pierce Anthony T | Director | Grant | 7.89K | — |
| 2026-06-02 | Lee Howard | Director | Withheld for tax | 769 | $14.19K |
| 2026-06-01 | Lee Howard | Director | Grant | 8.14K | — |
| 2026-06-01 | PRINS RICHARD K | Director | Grant | 8.14K | — |
| 2026-06-01 | Gaugh David Russell | Director | Grant | 8.14K | — |
| 2026-06-01 | Deflin Gayle | Director | Grant | 8.14K | — |
| 2026-06-01 | ZASLOFF MICHAEL A | Director | Grant | 8.14K | — |
Flow & Concentration
| Insider 180d net | -$345.74K |
|---|---|
| Insider buys / sells | 0 / 2 |
| Insider bias | Neutral |
| 13F holders | 0 |
| Top-5 share | 0.0% |
| HHI | 0 (—) |
SEC Filings
The Long Run
FY 2014–2025 · 12 years
| Line | Latest | CAGR | Trend |
|---|---|---|---|
| Revenue | $644.39M | +24.2% | |
| Gross profit | $356.06M | +19.3% | |
| Operating income | $196.99M | +29.2% | |
| Net income | $159.52M | +68.2% | |
| Cash from ops | $156.12M | +39.8% |
Indices
Recent Sessions
| Date | Open | High | Low | Close | Vol |
|---|---|---|---|---|---|
| Sep 25 | $26.25 | $26.63 | $25.66 | $26.13 | 376.90K |
| Sep 24 | $24.81 | $26.31 | $24.65 | $26.27 | 572.10K |
| Sep 23 | $24.39 | $25.12 | $24.20 | $24.96 | 508.10K |
| Sep 22 | $24.60 | $24.83 | $24.00 | $24.32 | 522.40K |
| Sep 21 | $23.54 | $25.41 | $23.45 | $24.48 | 595.80K |
Understand the score. Research layers are inputs to a model, and the available data has limits.
Read the methodology →